ReviewInternational journal of nanomedicine2026
Emerging Nanoplatforms are Effective Against Tumor Hypoxia.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia is a characteristic feature of the solid tumor microenvironment and serves as a pivotal factor in tumor progression, metastasis, and therapeutic resistance. It has long been recognized as a significant barrier to advancing cancer therapy. Although traditional oxygen supplementation strategies can partially enhance local oxygen levels, their effectiveness is limited by the spatiotemporal heterogeneity of tumor tissues, low delivery efficiency, and biosafety concerns, making them inadequate for the precise oxygen regulation required by the complex tumor microenvironment. In recent years, nanotechnology-based platforms designed to alleviate hypoxia have emerged as innovative approaches for remodeling the tumor microenvironment and enhancing multimodal synergistic therapies. These platforms operate through three primary strategies: exogenous oxygen delivery, endogenous oxygen generation, and metabolic oxygen conservation. This review systematically elucidates the underlying mechanisms of tumor hypoxia, summarizes the design principles and recent advancements of related nanomedicines, and discusses the potential and challenges of these platforms in multimodal combination therapies. The study aims to furnish a comprehensive reference for the design of hypoxia-alleviating nanoplatforms and the optimization of synergistic therapeutic strategies, with the objective of providing novel insights and prospects for the development of nanomaterials in this domain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.